Skip to main content

Table 3 Outcome variables in dogs on two different enzyme treatments for canine exocrine pancreatic insufficiency

From: A blinded randomised controlled trial to determine the effect of enteric coating on enzyme treatment for canine exocrine pancreatic insufficiency

Criterion

Treatment group

P value

Test (coated)

Control (uncoated)

Time

Time-group

Body weight (kg)

Before

21 ±8.8 (4 to 36)

26 ±10.3 (6 to 48)

---

0.159

14 days

23 ±9.3 (5 to 40)

26 ±10.1 (7 to 48)

0.962

0.012

28 days

24 ±9.6 (5 to 39)

27 ±10.6 (8 to 48)

0.145

0.004

56 days

25 ±10.0 (6 to 39)

28 ± 10.6 (8 to 48)

<0.001

<0.001

Body condition score1

Before

2 (1 to 5)

2 (1 to 6)

---

0.233

14 days

3 (1 to 5)

2 (1 to 6)

0.018

0.800

28 days

3 (1 to 5)

2 (1 to 6)

<0.001

0.593

56 days

4 (2 to 5)

3 (1 to 6)

<0.001

0.032

Dose of enzyme2

Before

2 (1 to 2)

2 (1 to 4)

---

0.669

14 days

2 (1 to 4)

2 (1 to 7)

0.075

0.311

28 days

2 (1 to 4)

2 (1 to 7)

0.002

0.722

56 days

2 (1 to 4)

4 (1 to 6)

<0.001

0.225

Clinical score3

Before

11 (4 to 19)

13 (2 to 16)

---

0.993

14 days

8 (2 to 12)

7 (2 to 15)

0.003

0.337

28 days

7 (1 to 13)

5 (0 to 11)

0.008

0.476

56 days

7 (1 to 13)

5 (0 to 11)

0.011

0.869

Other therapy

Before

Oxytetracycline (1)

Cimetidine (1)

---

---

14 days

Oxytetracycline (2)

Oxytetracycline (1)

---

---

28 days

Oxytetracycline (2)

Cimetidine (1) Metronidazole (1) Oxytetracycline (2)

---

---

56 days

Oxytetracycline (1)

Oxytetracycline (3) Ranitidine (1)

---

---

  1. Dogs, with exocrine pancreatic insufficiency, were randomised to receive one of two enzyme treatments (test [e.g. coated] and control [e.g. uncoated]). Numerical data are expressed as median (range), except for body weight, which is expressed as mean ± standard deviation (range). 1Body condition score assessed using the 9-point system [5]. 2 Dose of enzyme in number of capsules per day. 3Clinical score was a composite score for a range of clinical signs, as described in Table 3. Body weight increased progressively in dogs on both treatments (P<0.001), but a significant time-group interaction was evident with the magnitude of increase being greater for the test treatment (coated enzyme) than for the control treatment (uncoated enzyme; P<0.001). BCS increased over time in both groups (P<0.001), but increased more in the test treatment group (P=0.032 at 56 days). The dose of enzyme used increased (P<0.001 at 56 days) and whilst clinical disease severity score decreased (P=0.011 at 56 days) over time, but with no significant treatment group differences noted.